
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
Paras Biopharmaceuticals Finland Oy Paras Finland (Europe) is a fast growing biopharmaceutical technology development company which has successfully developed the proprietary Diabrid Platform Technology for the high level expression of biosimilars and long therapeutic peptides in specially designed genetically stable clones. Paras Biopharmaceuticals Finland Oy is specialized in design, development and optimization of manufacturing technologies for therapeutic peptides and soon to be off patent biologics. The company is building a robust portfolio of proprietary technologies and has developed extensive intellectual property. Paras has developed multiple novel technologies, 1. Diabrid Technology 2. NobleCleavTechnologies 3. Biomultifold Technology 4. Cytoplasmic Protein Folding Technologies...
Offering biosimilar technologies for economical scale up production of apis,diabrid technology for production of long therapeutic peptides,and noblecleav technologies for the production of difficult proteins efficiently
Paras biopharmaceuticals finland operates in the Pharmaceutical manufacturing industry.
Paras biopharmaceuticals finland's revenue is 11m - 100m
Paras biopharmaceuticals finland has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.